Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

B. Besse, C. Springfeld, C. Baik, A. Hervieu, B. Solomon, V. Moreno, L. Bazhenova, K. Goto, Y. C. Kim, S. Lu, M. Sun, D. Trone, S. Thamake, B. C. Cho, A. de Langen, S. Popat, J. Wolf, D. Moro-Sibilot, J. Fang, A. Drilon

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S75-S76
JournalEuropean Journal of Cancer
Publication statusPublished - 2022 Oct

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this